血と高感度C反応性タンパク質の血性指数と心血管疾患の関連:中年および高齢の中国人コホートからの証拠
PubMedで要約を見る
まとめ
この要約は機械生成です。血動脈指数 (AIP) と高感度C反応性タンパク質 (hs- CRP) の上昇は,心臓血管疾患 (CVD),特に脳卒中のリスクを大幅に増加させる. 高齢者のリスク予測を改善する可能性がある.
科学分野
- 心血管疾患の研究
- バイオマーカーの分析
- エピデミオロジー
背景
- 血性指数 (AIP) と高感度C反応性タンパク質 (hs- CRP) は心血管疾患 (CVD) と関連しています.
- AIPとhs-CRPがCVDリスクに及ぼす影響と相互作用のメカニズムについては,さらなる調査が必要である.
研究 の 目的
- AIPとhs-CRPのCVDリスクとの独立した関連性を評価する.
- CVDの発達におけるAIPとhs-CRPのメディエーション効果と添加的相互作用を探求する.
- 結合されたAIPとhs-CRPのCVDの予測性能を評価する.
主な方法
- 中国保健・退職長期研究 (CHARLS) の8,763人の成人 (≥45歳) のデータを利用し,最大9年間の追跡調査を行った.
- 多変数Coxモデル,メディエーション分析,相互作用による相対的過剰リスク (RERI) を用いて,関連と相互作用を評価した.
- 受信機操作特性 (ROC) 曲線解析を用いて予測性能を評価した.
主要な成果
- AIPとhs- CRPの値が高くなるのは,独立して心血管疾患のリスクの増加と関連していた.
- AIPとhs-CRPの両方のレベルが上昇した個人は,特に脳卒中 (HR: 2,207) のために,最も高いCVDリスクを示しました.
- hs- CRPはAIP- CVD関連性の6. 6%,AIPはhs- CRP- CVD関連性の20. 3%を媒介し,潜在的陽性添加相互作用が観察された (RERI=0. 141).
- 統合モデルでは,個々のマーカーと比較して優れたCVD予測 (AUC=0. 590) が示され,脳卒中予測の最適性能 (AUC=0. 615) が示された.
結論
- AIPとhs-CRPの合同上昇は,心血管疾患と脳卒中のリスクを大幅に増加させます.
- 相互の媒介と潜在的添加的相互作用は,CVDの病原性における脂質代謝と炎症の相互関係を示唆する.
- AIPとhs-CRPの両方をリスク評価モデルに統合することで,中年および高齢者の早期CVD検出と予防戦略を向上させることができます.
関連する概念動画
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

